| Operations and Assets for Operating Segments and Geographic Information |
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
For the six months ended June 30, |
(In thousands) |
2019 |
|
2018 |
|
2019 |
|
2018 |
Revenue from services: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Diagnostics |
178,458 |
|
|
216,055 |
|
|
357,349 |
|
|
427,369 |
|
Corporate |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
$ |
178,458 |
|
|
$ |
216,055 |
|
|
$ |
357,349 |
|
|
$ |
427,369 |
|
Revenue from products: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
28,680 |
|
|
$ |
28,523 |
|
|
$ |
53,981 |
|
|
$ |
56,374 |
|
Diagnostics |
— |
|
|
— |
|
|
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
$ |
28,680 |
|
|
$ |
28,523 |
|
|
$ |
53,981 |
|
|
$ |
56,374 |
|
Revenue from transfer of intellectual property and other: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
19,230 |
|
|
$ |
19,107 |
|
|
$ |
37,490 |
|
|
$ |
34,855 |
|
Diagnostics |
— |
|
|
— |
|
|
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
$ |
19,230 |
|
|
$ |
19,107 |
|
|
$ |
37,490 |
|
|
$ |
34,855 |
|
Operating loss: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
(8,556 |
) |
|
$ |
2,165 |
|
|
$ |
(38,033 |
) |
|
$ |
(20,783 |
) |
Diagnostics |
(28,013 |
) |
|
1,475 |
|
|
(61,582 |
) |
|
(6,543 |
) |
Corporate |
(10,691 |
) |
|
(8,748 |
) |
|
(22,962 |
) |
|
(20,393 |
) |
|
$ |
(47,260 |
) |
|
$ |
(5,108 |
) |
|
$ |
(122,577 |
) |
|
$ |
(47,719 |
) |
Depreciation and amortization: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
7,382 |
|
|
$ |
6,752 |
|
|
$ |
14,908 |
|
|
$ |
13,492 |
|
Diagnostics |
16,260 |
|
|
17,989 |
|
|
32,530 |
|
|
35,975 |
|
Corporate |
19 |
|
|
21 |
|
|
39 |
|
|
51 |
|
|
$ |
23,661 |
|
|
$ |
24,762 |
|
|
$ |
47,477 |
|
|
$ |
49,518 |
|
Loss from investment in investees: |
|
|
|
|
|
|
|
Pharmaceutical |
$ |
(271 |
) |
|
$ |
(6,942 |
) |
|
$ |
(2,125 |
) |
|
$ |
(9,114 |
) |
Diagnostics |
— |
|
|
(271 |
) |
|
— |
|
|
(555 |
) |
Corporate |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
$ |
(271 |
) |
|
$ |
(7,213 |
) |
|
$ |
(2,125 |
) |
|
$ |
(9,669 |
) |
Revenues: |
|
|
|
|
|
|
|
United States |
$ |
184,310 |
|
|
$ |
222,535 |
|
|
$ |
369,203 |
|
|
$ |
437,845 |
|
Ireland |
22,174 |
|
|
20,778 |
|
|
42,707 |
|
|
38,060 |
|
Chile |
9,051 |
|
|
11,937 |
|
|
16,915 |
|
|
23,670 |
|
Spain |
4,876 |
|
|
4,592 |
|
|
9,294 |
|
|
10,125 |
|
Israel |
3,768 |
|
|
2,526 |
|
|
6,884 |
|
|
6,141 |
|
Mexico |
2,058 |
|
|
1,302 |
|
|
3,589 |
|
|
2,723 |
|
Other |
131 |
|
|
15 |
|
|
228 |
|
|
34 |
|
|
$ |
226,368 |
|
|
$ |
263,685 |
|
|
$ |
448,820 |
|
|
$ |
518,598 |
|
|
|
|
|
|
|
|
|
|
(In thousands) |
June 30,
2019 |
|
December 31,
2018 |
Assets: |
|
|
|
Pharmaceutical |
$ |
1,239,338 |
|
|
$ |
1,236,499 |
|
Diagnostics |
1,138,673 |
|
|
1,162,160 |
|
Corporate |
78,217 |
|
|
52,413 |
|
|
$ |
2,456,228 |
|
|
$ |
2,451,072 |
|
Goodwill: |
|
|
|
Pharmaceutical |
$ |
247,055 |
|
|
$ |
247,407 |
|
Diagnostics |
452,787 |
|
|
452,786 |
|
Corporate |
— |
|
|
— |
|
|
$ |
699,842 |
|
|
$ |
700,193 |
|
|